Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma

Table 1 Baseline characteristics of both groups

	cTACE (n = 174)		DEB TACE (n = 76)
	n	%	n	%	p
Patient demographics
Sex					0.17
Male	144	82.8	68	89.5
Female	30	17.2	8	10.5
Age (years)					0.04
<60	46	26.4	11	14.5
≥60	128	73.6	65	85.5
Etiology of liver cirrhosis^a
Alcohol					0.15
Yes	86	49.4	30	39.5
No	88	50.6	46	60.5
HCV					0.91
Yes	47	27.0	20	26.3
No	127	73.0	56	73.7
HBV					0.21
Yes	14	8.0	10	13.2
No	160	92.0	66	86.8
NASH					0.29
Yes	10	5.7	2	2.6
No	164	94.3	74	97.4
Cryptogen					0.01
Yes	5	2.9	8	10.5
No	169	97.1	68	89.5
Prior curative treatment					0.01
Yes	17	9.8	17	22.4
No	157	90.2	59	77.6
Liver function/patient status
BCLC					0.21
A	30	17.2	8	10.5
B	59	33.9	34	44.7
C	77	44.3	30	39.5
D	8	4.6	4	5.3
ECOG					0.44
0	110	63.2	53	69.7
1	61	35.1	20	26.3
2	2	1.1	2	2.6
3	1	0.6	1	1.3
Portal invasion					0.25
Yes	36	20.7	11	14.5
No	138	79.3	65	85.5
Metastasis					0.66
Yes	5	2.9	3	3.9
No	169	97.1	73	96.1
Child					0.48
A	103	59.2	51	67.1
B	64	36.8	22	28.9
C	7	4.0	3	3.9
Bilirubin (mg/dl)					0.40
<2	136	78.2	64	84.2
2-3	24	13.8	9	11.8
>3	14	8.0	3	3.9
Albumin (mg/dl)					0.54
>3.5	76	43.7	29	38.2
2.8-3.5	67	38.5	35	46.1
<2.8	31	17.8	12	15.8
INR					0.35
<1.7	172	98.9	76	100.0
1.7-2.3	2	1.1	0	0.0
>2.3	0	0.0	0	0.0
Ascites					0.55
None	118	67.8	61	80.3
Mild	38	21.8	11	14.5
Moderate to severe	18	10.3	4	5.3
Hepatic encephalopathy					0.26
None	173	99.4	75	98.7
Grade I-II	1	0.6	1	1.3
Grade III-IV	0	0.0	0	0.0
Tumor characteristics
Tumor grading					0.08
G1	80	46.0	34	44.7
G2	82	47.1	30	39.5
G3	12	6.9	12	15.8
Milan criteria					0.13
In	47	27.0	14	18.4
Out	127	73.0	62	81.6
SLD (cm)					0.93
<3	19	10.9	8	10.5
≥3	155	89.1	68	89.5

HBV hepatitis B virus, HCV hepatitis C virus, NASH nonalcoholic steatohepatitis, BCLC barcelona clinic liver cancer classification, ECOG eastern cooperative oncology group, INR international normalized ratio, SLD sum of the longest diameter
^a5 patients with HBV/HCV co-infection

ISSN: 1471-2407